로딩 중…
지수 로딩 중…
C&R Research Inc.
359090· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩1,878+3.76%
2026-08-04
Financials
Valuation Metrics
C&R Research Inc.'s Market Cap is ₩216B. At end of 2025 it was ₩517B. Ranked #2278 of 2,436 in KR market (top 94%), #1503 of 1,649 on KOSDAQ (top 91%), #226 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 97%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 21.59B KRW | KR#2,278/2,436 Sec#226/234 |
| Revenue | 62.70B KRW | KR#1,665/2,436 Sec#111/234 |
| Net Income | 326.7M KRW | KR#1,480/2,436 Sec#103/234 |
| Total Assets | 90.52B KRW | KR#1,827/2,436 Sec#149/234 |
| Net Assets | 45.86B KRW | KR#1,937/2,436 Sec#168/234 |
| Employees | 518 | KR#479/2,436 Sec#40/234 |
| Value | ||
| P/E | 66.07x | KR#1,392/2,436 Sec#91/234 |
| P/B | 0.47x | KR#725/2,436 Sec#24/234 |
| PEG | 0.51x | KR#663/2,436 Sec#40/234 |
| P/S | 0.34x | KR#673/2,436 Sec#15/234 |
| EV/EBITDA | 44.33x | KR#1,307/2,436 Sec#88/234 |
| Profitability | ||
| ROE | 0.71% | KR#1,444/2,436 Sec#100/234 |
| ROA | 0.36% | KR#1,435/2,436 Sec#101/234 |
| Op. Margin | 1.00% | KR#1,478/2,436 Sec#108/234 |
| Revenue Growth | -13.39% | KR#1,956/2,436 Sec#179/234 |
| Earnings Growth | 130.63% | KR#352/2,436 Sec#25/234 |
| Financial Health | ||
| Debt Ratio | 197.39% | KR#1,700/2,436 Sec#188/234 |
| Total Debt | 14.50B KRW | KR#1,492/2,436 Sec#132/234 |
| Cash | 8.38B KRW | KR#1,771/2,436 Sec#149/234 |
| Current Ratio | 1.00x | KR#1,820/2,436 Sec#183/234 |
| Net Debt/EBITDA | 9.79x | KR#1,267/2,436 Sec#90/234 |
| Dividend | ||
| Div. Yield | 2.76% | KR#712/2,436 Sec#38/234 |
| Div. Growth | 0.00% | KR—/2,436 Sec—/234 |
| Performance | ||
| 1Y Return | -63.21% | KR#2,278/2,436 Sec#216/234 |
| 1M Return | 2.96% | KR#704/2,436 Sec#55/234 |
| From 52W High | -68.12% | KR#2,045/2,436 Sec#180/234 |
| 1Y MDD | -69.17% | KR#1,916/2,436 Sec#163/234 |
| Trading | ||
| Volume | 8,618 shares | KR#2,099/2,436 Sec#206/234 |
| Foreign Own. | 1.18% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | 211 KRW | KR#1,183/2,436 Sec#82/234 |
| BPS | 4,186 KRW | KR#1,583/2,436 Sec#121/234 |
Company Info
CEO 윤문태
Employees 518
Founded 2020
HQ 서울특별시 강남구, KR
동사는 2000년 법인 전환 설립되었으며, 2021년 엔에이치기업인수목적17호와 합병 후 코스닥시장 상장함. 임상시험수탁기관으로 신약개발 임상시험 설계, 컨설팅, 모니터링, 데이터 관리 등 전 영역 서비스를 제공하고 있음. 임상시험 IT 솔루션 LeadTrial EDC, CTMS, CsafeR 개발 완료하며, 글로벌 시장 진출 위해 서울대병원과 협력하여 다지역 임상시험 서비스 제공하고 있음. 씨엔알리서치는 2020년에 설립되었으며 서울특별시 강남구에 본사를 두고 있습니다.